ConforMIS

ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm's products include iUni, iDuo, iTotal CR, and iTotal. The company was founded by Philipp Lang in 2004 and is headquartered in Billerica, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which it refers to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers.

DURHAM, N.C.--(BUSINESS WIRE)-- #3DPrinting--On September 5, 2023, restor3d, Inc. finalized its previously announced acquisition of Conformis, Inc. With this merger complete, there is tremendous opportunity to deliver clinically differentiated and cost-effective solutions across the orthopaedic landscape. “We are thrilled to announce the successful achievement of one of our key initiatives post-acquisition,” stated Kurt Jacobus, Chief Executive Officer of restor3d. “Patient-specific femoral implants, which h.

Scaling a Personalized Portfolio: restor3d Completes Key Initiative Following Conformis Acquisition

Combination Creates the World's Preeminent Producer of Personalized Orthopedic Medical Devices, with Unmatched Additive Manufacturing Capabilities Combination Creates the World's Preeminent Producer of Personalized Orthopedic Medical Devices, with Unmatched Additive Manufacturing Capabilities

restor3d Completes Acquisition of Conformis

BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS ), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d.

Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote “FOR” the Pending Merger with restor3d

ConforMIS (CFMS) came out with a quarterly loss of $1.78 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to loss of $2.25 per share a year ago.

ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates

BILLERICA, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2023.

Conformis Reports Second Quarter 2023 Financial Results

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Conformis, Inc. (NasdaqCM: CFMS) to restor3d, Inc. Under the terms of the proposed transaction, shareholders of Conformis will receive $2.27 in cash for each share of Conformis that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the cons.

CONFORMIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Conformis, Inc. - CFMS

MILWAUKEE , June 23, 2023 /PRNewswire/ -- Ademi LLP is investigating Conformis (NASDAQ: CFMS) for possible breaches of fiduciary duty and other violations of law in its transaction with restor3d.  Click here to learn how to join the action https://www.ademilaw.com/case/conformis-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Conformis, Inc. has obtained a Fair Price in its transaction with restor3d

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Conformis, Inc. (NASDAQ: CFMS) to restor3d for $2.27 per share in cash is fair to Conformis shareholders. Halper Sadeh encourages Conformis shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Conformis and its boar.

CFMS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Conformis, Inc. Is Fair to Shareholders

Shares of Conformis Inc. CFMS, -2.11% rocketed 90.5% to pace all premarket gainers in active trading Friday, after the orthopedic patient care company announced an agreement to be acquired by Restor3d for a 96% premium. Trading volume swelled to more than 671,000 shares, compared with the full-day average of about 52,800 shares.

Conformis stock nearly doubles in active trading after cash buyout deal with Restor3d

Combination creates a leading personalized 3D-printed orthopedic medical device company Combination creates a leading personalized 3D-printed orthopedic medical device company

Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in Cash

ConforMIS (CFMS) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.56. This compares to loss of $2.25 per share a year ago.

ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates

Conformis, Inc. (NASDAQ:CFMS ) Q1 2023 Earnings Conference Call May 8, 2023 8:30 AM ET Company Participants Mark Augusti - President and CEO Bob Howe - CFO and Treasurer Conference Call Participants Eric Anderson - TD Cowen Steve Lichtman - Oppenheimer Joshua Jennings - TD Cowen Operator Good morning, and welcome to the First Quarter 2023 Earnings Conference Call for Conformis, Incorporated. My name is Tanya, and I will be your conference operator today.

Conformis, Inc. (CFMS) Q1 2023 Earnings Call Transcript

BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2023.

Conformis Reports First Quarter 2023 Financial Results

BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023.

Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023

The campaign underscores that patients have a choice of implant when undergoing total knee arthroscopy, and that they should advocate for the many benefits of a fully personalized knee The campaign underscores that patients have a choice of implant when undergoing total knee arthroscopy, and that they should advocate for the many benefits of a fully personalized knee

Conformis Launches Patient Awareness Campaign to Highlight the Benefits of Personalized Knee Replacement Procedures

ConforMIS (CFMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ConforMIS (CFMS) Moves to Buy: Rationale Behind the Upgrade

Conformis, Inc. (NASDAQ:CFMS ) Q4 2022 Results Conference Call March 1, 2023 4:30 PM ET Company Participants Mark Augusti - President and Chief Executive Officer Bob Howe - CFO and Treasurer Conference Call Participants Steven Lichtman - Oppenheimer Eric Anderson - Cowen Operator Good afternoon, and welcome to the Fourth Quarter and Full Year 2022 Earnings Conference Call for Conformis, Inc. My name is Josh, and I will be your conference operator today. All lines have been placed on listen-only mode to prevent any background noise.

Conformis, Inc. (CFMS) Q4 2022 Earnings Call Transcript

BILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022.

Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results

BILLERICA, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate at two upcoming investor conferences.

Conformis, Inc. to Participate in Upcoming Investor Conferences

Conformis and Bodycad Settle Litigation Related to Bodycad's Patient-Specific Instruments and Implants Conformis and Bodycad Settle Litigation Related to Bodycad's Patient-Specific Instruments and Implants

Conformis, Inc., Bodycad Laboratories, Inc. and Bodycad USA Corp. Announce Settlement of Patent Litigation

Company Launches New Advertising Campaign Company Launches New Advertising Campaign

Conformis Provides Business Update and Reports Preliminary Results for Fourth Quarter and Full-Year 2022

BILLERICA, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the fourth quarter and full-year ended December 31, 2022, after the market closes on Wednesday, March 1, 2023.

Conformis, Inc. to Announce Financial Results for Its Fourth Quarter and Full-Year 2022

BILLERICA, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it received a letter from the Listing Qualifications Department of The NASDAQ Stock Market (“NASDAQ”) on November 25, 2022 notifying Conformis that, based on the closing bid price of Conformis' common stock having been $1.00 per share or greater on each of the trading days from November 10, 2022 to November 23, 2022, Conformis has regained compliance with Nasdaq Listing Rule 5550(a)(2) and the minimum bid price deficiency matter previously disclosed by Conformis is now closed.

Conformis, Inc. Regains Compliance with Nasdaq's Minimum Bid Price Rule

First Actera™ procedure underscores company's ongoing commitment to advancing joint replacement technology by leveraging its data-driven approach and surgical planning expertise First Actera™ procedure underscores company's ongoing commitment to advancing joint replacement technology by leveraging its data-driven approach and surgical planning expertise

Conformis Announces First Procedure Performed Using New Actera™ Hip System

Conformis' Imprint™ knee system introduces the new “Made-to-Measure” product category option for Total Knee Arthroplasty (TKA) Conformis' Imprint™ knee system introduces the new “Made-to-Measure” product category option for Total Knee Arthroplasty (TKA)

News for ConforMIS Stock (CFMS)